C
C. Michael Gibson
Researcher at Harvard University
Publications - 21
Citations - 22138
C. Michael Gibson is an academic researcher from Harvard University. The author has contributed to research in topics: TIMI & Myocardial infarction. The author has an hindex of 19, co-authored 21 publications receiving 20076 citations. Previous affiliations of C. Michael Gibson include Allegheny General Hospital & University of California, San Francisco.
Papers
More filters
Journal ArticleDOI
Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes
Stephen D. Wiviott,Eugene Braunwald,Carolyn H. McCabe,Gilles Montalescot,Witold Rużyłło,Shmuel Gottlieb,Franz Joseph Neumann,Diego Ardissino,Stefano De Servi,Sabina A. Murphy,Jeffrey S. Riesmeyer,Govinda Weerakkody,C. Michael Gibson,Elliott M. Antman +13 more
TL;DR: In patients with acute coronary syndromes with scheduled percutaneous coronary intervention, prasugrel therapy was associated with significantly reduced rates of ischemic events, including stent thrombosis, but with an increased risk of major bleeding, including fatal bleeding.
Journal ArticleDOI
Standardized Bleeding Definitions for Cardiovascular Clinical Trials A Consensus Report From the Bleeding Academic Research Consortium
Roxana Mehran,Sunil V. Rao,Deepak L. Bhatt,C. Michael Gibson,Adriano Caixeta,John W. Eikelboom,Sanjay Kaul,Stephen D. Wiviott,Venu Menon,Eugenia Nikolsky,Victor L. Serebruany,Marco Valgimigli,Pascal Vranckx,David P. Taggart,Joseph F. Sabik,Donald E. Cutlip,Mitchell W. Krucoff,E. Magnus Ohman,Philippe Gabriel Steg,Harvey D. White +19 more
TL;DR: Bleeding complications have been associated with an increased risk of subsequent adverse outcomes, including MI, stroke, stent thrombosis, and death, in patients with ACS and in those undergoing percutaneous coronary intervention (PCI) as well as in the long-term antithrombotic setting.
Journal ArticleDOI
Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban.
Christopher P. Cannon,William S. Weintraub,Laura A. Demopoulos,Ralph Vicari,Martin J. Frey,Nasser Lakkis,Franz-Josef Neumann,Debbie H. Robertson,Paul DeLucca,Peter M. DiBattiste,C. Michael Gibson,Eugene Braunwald +11 more
TL;DR: In patients with unstable angina and myocardial infarction without ST-segment elevation who were treated with the glycoprotein IIb/IIIa inhibitor tirofiban, the use of an early invasive strategy significantly reduced the incidence of major cardiac events.
Journal ArticleDOI
Addition of Clopidogrel to Aspirin and Fibrinolytic Therapy for Myocardial Infarction with ST-Segment Elevation
Marc S. Sabatine,Christopher P. Cannon,C. Michael Gibson,Jose Lopez-Sendon,Gilles Montalescot,Pierre Theroux,Marc J. Claeys,Frank Cools,Karen A. Hill,Allan M. Skene,Carolyn H. McCabe,Eugene Braunwald +11 more
TL;DR: A substantial proportion of patients receiving fibrinolytic therapy for myocardial infarction with ST-segment elevation have inadequate reperfusion or reocclusion of the infarct-related artery, leading to an increased risk of complications and death as discussed by the authors.
Journal ArticleDOI
Rivaroxaban in Patients with a Recent Acute Coronary Syndrome
Jessica L. Mega,Eugene Braunwald,Stephen D. Wiviott,Jean-Pierre Bassand,Deepak L. Bhatt,Christoph Bode,Paul Burton,Marc Cohen,Nancy Cook-Bruns,Shinya Goto,Sabina A. Murphy,Alexei N. Plotnikov,David J. Schneider,Xiang Sun,C. Michael Gibson +14 more
TL;DR: In patients with a recent acute coronary syndrome, rivaroxaban reduced the risk of the composite end point of death from cardiovascular causes, myocardial infarction, or stroke in a double-blind, placebo-controlled trial.